Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Rybelsus 7 mg {equilateral_black_triangle}

Active Ingredient:
semaglutide
Company:  
Novo Nordisk Limited See contact details
ATC code: 
A10BJ06
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Letters to HCPs HCP Med Info
{arrow_left}
{arrow_right}

Important information for Healthcare Professionals

{pdf_link}

Ozempic® (Semaglutide), Victoza® (Liraglutide): GLP-1 Receptor Agonists Supply Shortage in the UK- Updates for Prescribers

{healthcare_pro_orange} For Healthcare Professionals
Novo Nordisk is experiencing supply shortages for the glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in the UK: - Ozempic 0.25 mg, 0.5 mg, 1 mg solution for injection in pre-filled pen (semaglutide) - Victoza 6mg/ml solution for injection in pre-filled pen (liraglutide)

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Novo Nordisk Limited
Company image
Address
3 City Place, Beehive Ring Road, Gatwick, West Sussex, RH6 0PA
Telephone
+44 (0)1293 613555
Fax
+44 (0)1293 613535
Customer Care direct line
+44 (0)800 023 2573
Medical Information Direct Line
+44 (0)800 023 2573
Medical Information e-mail
[email protected]
WWW
http://www.novonordisk.co.uk